**Abstract**

***Objective:*** Many kinds of antidepressants, such as tricyclic antidepressants and selective serotonin reuptake inhibitors (SSRIs) have been developed, whereas approximately 30 % of patients with major depressive disorder are \"treatment-resistant depression\", which is resistant to existing antidepressants. SSRIs are the first-line antidepressants in the treatment of major depressive disorder, and directly bind to the serotonin transporter (SERT). SERT activity is attenuated by PKC, which induced SERT phosphorylation and surface expression, thereby SERT is a key regulator of SERT-serotonergic functions. The present study was investigated whether PKC is related to depressive behaviors in the forced swimming-stressed mice, and further they are mediated via SERT function in stressed mice.

***Method:*** Mice were forced to swim (the 1st swimming: stressed mice) to get the immobility time stable at the 2nd swimming. On the next day, they were forced to swim again (the 2nd swimming: tested mice), and 20 min later, they were performed the social interaction test. The effects of phorbol 12-myristate 13-acetate (PMA: a PKC activator), imipramine or sertraline (an antidepressant), and chelerythrine (a PKC inhibitor) on the performance of behavioral tests were examined, and PKC activity and SERT expression were analyzed.

***Result:*** The expression levels of phosphorylated SERT protein were decreased in tested mice. PMA as well as antidepressants attenuated the immobility and deficits of social behaviors in tested mice. It also increased in the expression levels of phosphorylated PKC and SERT proteins. Chelerythrine exacerbated both behavioral abnormalities in tested mice and decreased the expression levels of phosphorylated PKC protein.

***Conclusion:*** These results suggest that the PKC activator attenuates some depressive behaviors in stressed mice to promote metabolism of SERT via phosphorylation PKC, and it might be a novel antidepressant.
